Affordable Access

deepdyve-link
Publisher Website

Synthesis and biological evaluation of semi-synthetic albocycline analogs.

Authors
  • Daher, Samer S1
  • Franklin, Kevin P1
  • Scherzi, Tyler2
  • Dunman, Paul M2
  • Andrade, Rodrigo B3
  • 1 Department of Chemistry, Temple University, Philadelphia, PA 19122, United States. , (United States)
  • 2 Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, United States. , (United States)
  • 3 Department of Chemistry, Temple University, Philadelphia, PA 19122, United States. Electronic address: [email protected] , (United States)
Type
Published Article
Journal
Bioorganic & medicinal chemistry letters
Publication Date
Aug 19, 2020
Volume
30
Issue
21
Pages
127509–127509
Identifiers
DOI: 10.1016/j.bmcl.2020.127509
PMID: 32827630
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Albocycline (ALB) is a unique macrolactone natural product with potent, narrow-spectrum activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate (VISA), and vancomycin-resistant S. aureus (VRSA) strains (MIC = 0.5-1.0 μg/mL). Described herein is the synthesis and evaluation of a novel series analogs derived from albocycline by functionalization at three specific sites: the C2-C3 enone, the tertiary carbinol at C4, and the allylic C16 methyl group. Exploration of the structure-activity relationships (SAR) by means of minimum inhibitory concentration assays (MICs) revealed that C4 ester analog 6 was twice as potent as ALB, which represents a class of lead compound that can be further studied to address multi-drug resistant pathogens. Copyright © 2020 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times